AU2009250169A1 - A combined method for predicting the response to an anti-cancer therapy - Google Patents

A combined method for predicting the response to an anti-cancer therapy Download PDF

Info

Publication number
AU2009250169A1
AU2009250169A1 AU2009250169A AU2009250169A AU2009250169A1 AU 2009250169 A1 AU2009250169 A1 AU 2009250169A1 AU 2009250169 A AU2009250169 A AU 2009250169A AU 2009250169 A AU2009250169 A AU 2009250169A AU 2009250169 A1 AU2009250169 A1 AU 2009250169A1
Authority
AU
Australia
Prior art keywords
fold
timp
dna
top2a
sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2009250169A
Other languages
English (en)
Inventor
Nils Aage Brunner
Bent Laursen Ejlertsen
Kirsten Vang Nielsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Dako Denmark ApS
Rigshospitalet
Original Assignee
Dako Denmark ApS
Rigshospitalet
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dako Denmark ApS, Rigshospitalet filed Critical Dako Denmark ApS
Publication of AU2009250169A1 publication Critical patent/AU2009250169A1/en
Assigned to DAKO DENMARK A/S, RIGSHOSPITALET reassignment DAKO DENMARK A/S Amend patent request/document other than specification (104) Assignors: DAKO DENMARK A/S
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/154—Methylation markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • General Engineering & Computer Science (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2009250169A 2008-05-20 2009-05-20 A combined method for predicting the response to an anti-cancer therapy Abandoned AU2009250169A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
DKPA200800696 2008-05-20
DKPA200800696 2008-05-20
US5494408P 2008-05-21 2008-05-21
US61/054,944 2008-05-21
PCT/DK2009/050116 WO2009140973A1 (en) 2008-05-20 2009-05-20 A combined method for predicting the response to an anti-cancer therapy

Publications (1)

Publication Number Publication Date
AU2009250169A1 true AU2009250169A1 (en) 2009-11-26

Family

ID=40010544

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2009250169A Abandoned AU2009250169A1 (en) 2008-05-20 2009-05-20 A combined method for predicting the response to an anti-cancer therapy

Country Status (7)

Country Link
US (1) US20110144047A1 (https=)
EP (1) EP2288729A1 (https=)
JP (1) JP2011520456A (https=)
CN (1) CN102099493A (https=)
AU (1) AU2009250169A1 (https=)
CA (1) CA2725171A1 (https=)
WO (1) WO2009140973A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6841609B2 (ja) 2015-07-10 2021-03-10 ３スキャン インコーポレイテッド 組織学的染色の空間的多重化
CN105524990A (zh) * 2015-12-30 2016-04-27 广州安必平医药科技股份有限公司 Her-2基因和/或top2a基因检测探针及其制备方法和试剂盒
CN105483255A (zh) * 2015-12-30 2016-04-13 广州安必平医药科技股份有限公司 Top2a基因检测探针及其制备方法和试剂盒

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2002014A1 (en) * 2006-04-01 2008-12-17 Dako Denmark A/S Method for performing prognoses for high-risk breast cancer patients using top2a gene aberrations

Also Published As

Publication number Publication date
CA2725171A1 (en) 2009-11-26
US20110144047A1 (en) 2011-06-16
CN102099493A (zh) 2011-06-15
EP2288729A1 (en) 2011-03-02
JP2011520456A (ja) 2011-07-21
WO2009140973A1 (en) 2009-11-26

Similar Documents

Publication Publication Date Title
ES2553264T3 (es) Métodos para la predicción del resultado clínico para inhibidores del receptor del factor de crecimiento epidérmico para pacientes de cáncer
Gomez-Roca et al. Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
Ting et al. ERCC1, MLH1, MSH2, MSH6, and βIII-tubulin: resistance proteins associated with response and outcome to platinum-based chemotherapy in malignant pleural mesothelioma
Fisher et al. Epidermal growth factor receptor overexpression is a marker for adverse pathologic features in papillary thyroid carcinoma
EP2145021A2 (en) Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
Ho et al. Promoter methylation status of HIN-1 associated with outcomes of ovarian clear cell adenocarcinoma
US11821900B2 (en) Method of selection for treatment of subjects at risk of invasive breast cancer
EP1735463A2 (en) Biomarkers and methods for determining sensitivity to epidermal growth factor receptor modulators in non-small cell lung cancer
Kassem et al. ERCC1 and ERCC2 as predictive biomarkers to oxaliplatin-based chemotherapy in colorectal cancer patients from Egypt
WO2016090323A1 (en) Dcis recurrence and invasive breast cancer
CN103238069B (zh) 肺癌和结直肠癌中的bard1同工型及其应用
Meert et al. Is there a relationship between c-erbB-1 and c-erbB-2 amplification and protein overexpression in NSCLC?
Serrano-Oviedo et al. Implication of VHL, ERK5, and HIF-1alpha in clear cell renal cell carcinoma: Molecular basis
JP2011500046A (ja) Ｅｔ−７４３治療のための予後分子マーカー
US20110144047A1 (en) Combined method for predicting the response to an anti-cancer therapy
Kothari et al. The prognostic significance of the triple negative phenotype in endometrial cancer
Cohen et al. Expression of P53, P27 and KI‐67 in colorectal cancer patients of various ethnic origins: Clinical and tissue microarray based analysis
Patel et al. Emerging Cancer Biomarkers for HNSCC Detection and Therapeutic Intervention
Teng et al. Elucidating the Correlation between Leupaxin as a Prognostic Biomarker and Immunotherapeutic Efficacy in Esophageal Squamous Cell Carcinoma
Teng et al. Leupaxin: A Prospective Therapeutic Target for Esophageal Squamous Carcinoma Treatment
WO2009145924A2 (en) Methods and materials for identifying patients at heightened risk for developing her2+ related brain tumors
JP6833226B2 (ja) 大腸がんの予後バイオマーカー
KR101188693B1 (ko) 피부 편평세포암 진단 또는 예후 마커인 ＰｒｘⅠ 및 이의 용도
Singhai et al. RETRACTED ARTICLE: Cancer biomarker HER-2/neu in breast cancer in Indian women
KR101179651B1 (ko) 피부 편평세포암 진단 또는 예후 마커인 ｎｑｏ-1 및 이의 용도

Legal Events

Date Code Title Description
DA3 Amendments made section 104

Free format text: THE NATURE OF THE AMENDMENT IS: AMEND THE NAME OF THE INVENTOR TO READ BRUNNER, NILS AAGE; NIELSEN,KIRSTEN VANG AND EJLERTSEN, BENT LAURSEN

MK4 Application lapsed section 142(2)(d) - no continuation fee paid for the application